-
Kansas City Fed Chief Says Inflation Is Still Running Too Hot
-
Oil Heads for Second Weekly Loss as Supply Surplus Emerges
-
Luxury Skincare Brand Faces Backlash Over Futurist Manifesto Aesthetic
-
Asian Markets Slide as AI Concerns Hit Chip Stocks
-
Brazil Faces Debt and Inflation Test as Lula Prepares Fourth Term
-
Canada Signals Openness to Chinese Automakers if US Trade Talks Fail
-
Canada Expands Asian Trade Push as US Negotiations Resume
-
US Mortgage Rate Falls for Fourth Week but Remains Above 7%
-
US Jobless Claims Rise to 200,000 but Layoffs Remain Historically Low
-
Italy Raises 2026 Growth View but Warns Energy Will Keep Inflation High
-
Godzilla Minus Zero Review: Takashi Yamazaki’s Anti-Nuclear Allegory
-
Euro-Area Growth Slows to 0.4% While Employment Stalls
-
DA Demands No-Work-No-Pay for Striking Municipal Workers in Coalition Talks
-
UK Economy Grows 0.7% in Third Quarter as Services Lead Expansion
-
US Wholesale Inflation Eases Monthly but Hits a Four-Year Annual High
-
India's Retail Inflation Reaches 6.09% as Food Prices Accelerate
-
India's Wholesale Inflation Jumps to 12.29% as Fuel Costs Surge
-
Malta Emerges as Premier Low-Season Destination for UK Travelers
-
China's October Activity Data Reveal a Weak Start to the Fourth Quarter
-
Japan's Economy Edges Into Contraction as Costly Oil Weighs on Demand
-
Philippines Urges ASEAN and China to Accelerate South China Sea Code of Conduct
-
UK Home Asking Prices Drop £6,745 in November Amid High Mortgage Rates
-
Mbeki Claims No Progress Since 2018; Author Cites Infrastructure and Economic Gains
-
Alex Georgiev Sets Personal Record to Win NCAA Pole Vault at Penn Relays
-
Qatar's Amir and Venezuelan Acting President Discuss Energy Cooperation
-
NuRAN Wireless Eliminates Floating-Price Preferred Overhang and Locks In a Fixed C$1.20 Conversion Price
-
SMX: The Future of Gold Will Be Defined by What We Know About It -Powering Verified Trade and Tokenisation
-
Aptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Results
-
Cardiff Lexington Announces Third Quarter 2026 Financial Results
-
Expecting a Refund but Owe Back Taxes? Clear Start Tax Explains How the IRS Offset Program Takes It First
-
MicroVision Lidar Powers Commercial Driverless Trucking at Scale with Kodiak AI
-
Rescue Intellitech Expands Professional Decontamination Portfolio for Fire Departments with DeconWasher(TM) Pro S
-
Westell Technologies, Inc. Announces Its Commencing a Tender Offer
-
SMX Brings a New Level of Transparency to Gold Trading Through trueGold Technology
-
Ainos Reports Third Quarter 2026 Results and Highlights Expanding AI Nose Commercial Momentum
-
Wi2Wi Reports 35% Revenue Growth to US$2.36M and Returns to Profitability with US$268K Net Income in Q3 2026
-
Sharecare Partners With HomeTown Health to Bring AskMD, Funded Through the GREAT Health Program, to More Rural Hospitals and Patients Across Georgia
-
Gladstone Capital Corporation Earnings Call and Webcast Information
-
Medical Care Technologies Inc. (OTCID:MDCE) Follows Q3 Profit Surge With Confirmed Software Development and Expanding Subsidiary Activity
-
GameSquare Holdings Reports 2026 Third Quarter Results with Revenue up 77% YoY and Net Income Reaches $10.1 Million
-
ValorPay UAB Goes Live on T2, the Eurosystem's Real-Time Settlement System
-
CNS Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Progress in Establishing Transformative Therapeutic Pipeline
-
XCF Global Reports Third Quarter 2026 Financial Results & Affirms 2027 Outlook
-
NextSource Materials Appoints Eugene Lee as Chief Financial Officer
-
International Battery Metals Ltd. Reports Second Quarter of Fiscal Year 2027 Financial Results
-
Abasca Resources Engages Northern Arc Public Affairs to Advance Federal Engagement on the Loki Flake Graphite Project
-
AsiaFIN Holdings Corp. Announces Third Quarter 2026 Results, Reporting Strong Nine-Month Financial Performance with Improved Margins
-
Thalia Therapeutics PLC Announces Promising Interim Phase I Data for miRisten in AML
-
Strategic Metals Reports Promising Results From the Rusty and Ranch Projects
-
Golden Minerals Reports Third Quarter 2026 Financial Results
DEA Cannabis Poisoned, Zero Oversight-Massachusetts Lab Scandal: A Case Study in DEA's Regulatory Collapse
Poisoned Cannabis, Zero DEA Oversight
The DEA's mission statement is a sham under Thomas Prevoznik's watch. Americans are being poisoned by untested state cannabis operators while terminal patients are denied potential cures.
WASHINGTON, D.C. / ACCESS Newswire / July 6, 2025 / The Drug Enforcement Administration (DEA) exists to "prevent, detect, and investigate the diversion of controlled substances while ensuring an adequate and uninterrupted supply for legitimate medical, commercial, and scientific needs". Yet under the leadership of Deputy Administrator Thomas Prevoznik, the DEA's Diversion Control Division has catastrophically failed this mission. Instead of protecting public health, the agency has allowed contaminated cannabis to flood state markets-poisoning consumers-while simultaneously blocking federally compliant pharmaceutical research that could save lives. This is not just bureaucratic incompetence; it is systemic negligence bordering on malpractice.

1. DEA's Mission Failure: Poisoned Cannabis, Zero Oversight
The Massachusetts Scandal: A Case Study in Regulatory Collapse
In Massachusetts, Assured Testing Laboratories-a facility responsible for testing 25% of the state's cannabis-was caught falsifying safety reports, concealing contamination, and approving products that should have failed for yeast, mold, and microbial toxins. Thousands of tainted products reached consumers, yet the DEA:
Took no enforcement action
Issued no national recall
Failed to intervene despite its mandate to prevent diversion and ensure safety.
This is not an isolated incident. Across the U.S., unregulated cannabis markets operate like the "Wild West"-with no federal quality control, no uniform safety standards, and no accountability. The DEA, under Prevoznik, has abdicated its duty, leaving Americans exposed to dangerous products while offering no recourse.
2. Blocking Medical Breakthroughs: The DEA's War on Science
While turning a blind eye to contaminated street cannabis, the DEA has actively obstructed federally approved pharmaceutical research. MMJ BioPharma, a company developing cannabis-based treatments for Huntington's Disease and Multiple Sclerosis, has faced seven years of bureaucratic sabotage despite:
Holding FDA Investigational New Drug (IND) approvals
Securing Orphan Drug Designation for Huntington's therapy
Passing DEA security inspections.
Yet, Prevoznik's division refuses to grant MMJ a bulk manufacturing license, citing a retroactive "Bona Fide Supply Agreement" (BFSA) requirement that creates an impossible Catch-22:
No supplier will sign a contract without DEA approval.
DEA won't approve without a signed contract.
This obstruction is not just regulatory failure-it's deliberate stonewalling. As MMJ's legal filings reveal, DEA Administrative Law Judges (ALJs) operate in a structurally biased system, where registrants win only 20-25% of cases, and the DEA overturns nearly all pro-registrant rulings.
3. The Human Cost: Patients Suffer While Illicit Markets Thrive
The DEA's hypocrisy is staggering:
Patients with epilepsy, cancer, and neurological disorders are denied access to standardized, pharmaceutical-grade cannabis112.
Meanwhile, unregulated THC products-laced with pesticides, mold, and heavy metals-flood the market, making consumers sick 15.
Prevoznik's DEA has created the worst of both worlds:
No protection for consumers from tainted products.
No pathway for research into life-saving medicines.
4. Time for Accountability: Fire Prevoznik, Overhaul the DEA
The solution is clear:
Remove Thomas Prevoznik for gross negligence and regulatory malpractice.
Transfer cannabis oversight to the FDA/NIH, where science-not stigma-guides policy.
Investigate DEA's Diversion Control Division for systemic bias and corruption.
As MMJ BioPharma CEO Duane Boise stated:
"The DEA's Diversion Control Division, under Prevoznik's leadership, has failed to protect the public, failed to uphold science, and failed to meet even the most basic standards of competence."
Fire Thomas Prevoznik: A Call to Action
The DEA's mission statement is a sham under Prevoznik's watch. Americans are being poisoned by untested cannabis while terminal patients are denied potential cures. Congress must intervene, the courts must act, and the public must demand accountability.
Enough is enough. It's time to end the DEA's obstructionism and put public health over bureaucracy.
MMJ is Represented by Attorney Megan Sheahan and Associates
CONTACT:
Madison Hisey
[email protected]
203-231-8583
SOURCE: MMJ International Holdings
View the original press release on ACCESS Newswire
P.Hernandez--AT